Hanx Biopharmaceuticals (Wuhan) Co., Ltd. disclosed that it repurchased 2,100 H-shares on 21 April 2026, according to its Next Day Disclosure Return filed with the Hong Kong Stock Exchange on the same date. The transaction was executed on the Exchange at prices ranging from HKD 31.26 to HKD 31.70, with a volume-weighted average of HKD 31.65 per share, for a total outlay of HKD 66,462.

The repurchase represents 0.0015% of the company’s outstanding shares (excluding treasury shares) prior to the transaction. Following the buyback, issued shares outstanding fell from 135.97 million to 135.97 million, while treasury shares increased from 243,900 to 246,000. Total issued share capital remained unchanged at 136.22 million shares.

The purchases were made under the share-repurchase mandate approved on 12 February 2026, which allows Hanx Biopharma to repurchase up to 13.62 million shares. Cumulative buybacks under this mandate now stand at 246,000 shares, equivalent to 0.18% of shares outstanding on the mandate approval date.

In line with Hong Kong listing rules, the company is subject to a 30-day moratorium on issuing new shares or disposing of treasury shares, ending on 21 May 2026.